XERS - Earnings call transcript Q1 2022 | Xeris Biopharma Holdings, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello, and welcome to today’s Xeris Biopharma’s First Quarter 2022 Financial Results Conference Call and Webcast. My name is Bailey and I will be your moderator for today’s call. All lines will be muted during the presentation portion of the call, with an opportunity for questions-and-answers at the end. [Operator Instructions] I would now like to pass the conference over to Allison Wey, Senior Vice President of Investor Relations and Corporate Communications. Allison, please go ahead.

Allison Wey

Bailey. you, Thank welcome results and Biopharma's quarter first Good corporate to update financial and webcast. conference XXXX morning Xeris call and release website. first company's issued and with financial be press can our was morning earlier quarter on found results this A XXXX the

this provide Paul Edick, joined we financial and details Steve on CEO; Chairman opening provide will by Paul the then, questions. CFO. our our will morning call open remarks, are and and We Pieper, Steve for up will results

differ I to future Xeris' commercialization, may clinical like the Securities Harbor and of Safe other that the prospects, of impact call begin, Xeris' business on you the we concerning Litigation those under Before Reform provision results of third-party forward-looking Act result approvals, by SEC. the statements will indicated would Xeris' for a financial global of Actual filings our related as manufacturers and factors the effect purposes practices, suppliers business discussed this of remind factors, and corporate risk performance, from statements, clinical operations, included XXXX. contain the Private expectations, and condition, U.S. materially the business, pandemic with which the on uncertainties forward-looking COVID-XX statements important these various trials markets, strategy, those constitute Xeris' practices, plans, and including forward-looking in COVID-XX to

Paul. of upon update this now specifically the We of In addition, statements. as obligations subsequent as of any views be over the represent any call to forward-looking our any date statements disclaim as and only to turn I'll representing should views call our not such relied date.

Paul Edick

today. and joining us to thanks Thanks, Allison. morning everybody Good for

had $XX is in in net revenue. Our that good approximately of quarter product another for quarter headline million XXXX. We generated call very this first the we

strong continued prescription share Gvoke. for and We growth

Gvoke Kit, to of overall add the at the which to the end more patients and even became products the all in Recorlev, UK Gvoke, our Keveyis available and continue of quarter. We including

of strengthened refinancing, with a of dramatically over also addition debt gives us Phase pipe to year. with confidence study Hayfin, product. the million for our we the $XXX performance quarter track million finalized This levothyroxine and $XX We ending first that the the X advance with and great our the cash cash are in continue quarter we position on we

balance We guidance of acquisition therefore $XXX to previously XXXX. and of to are breakeven with $XX achieving XXXX, into product net for year by in Strongbridge from million performance, million starting highlights some our flow behind announced end in XXXX. million million $XX $XXX XXXX revenue million the our $XXX Gvoke. synergies cash cash year-end Year-end affirming total I'll realizing by go specific

compared year. prescriptions while the glucagon XX% continue We quarter, growth. In to X%. Gvoke impressive On see to Gvoke basis, the overall sequential grew market first Gvoke grew quarter a last first prescription X% quarter-over-quarter, declined

again, strong to to So the continue we Gvoke and market. for continues demand there be outpace

now offices. us prior better really versus improving, year growth has of about glucagon the have the offices market as to those prescriptions feel the holiday the but X,XXX week April XX% strong it For last had prescriptions, market started share, during out, those period, with April a we which flat in and second access quarter. the Overall, good are finished month been makes and balance opened the reps over watching

new are positioned prescriptions, in the continues market, to a formularies, the that of in encouraging. levels, overall terribly pre-pandemic very overall We good XX% which back also over is to we glucagon regional XXXX growth and balance well we very in the health work are UK, market (ph) to portion on XX%, not Gvoke of products as modest EU, are not to return the does when to believe in prescriptions of beginning pandemic they preadmit those than on growth outpace launching get in assuming over are is back we late Ready-to-use that capture see double-digit growth. of quite the uptake growth additional they While U.S. which Tetris now a also launch growth. XX% toward levels final early to the are to to Texas the process getting Ogluo XXXX. in in different countries payer continues to formularies Since glucagon

Keveyis. Moving on to

the patients in optimum benefiting to working PPP is team several weeks of as expertise of We months. are close so of a we number our very we to dose from testament relationship hard patients mentioned Year-over-year Onto discussed identify, starting clearing and to to on steady with Recorlev, launched previously. as this February as paralysis the time titrating one's the patients reimbursement the drug the healthcare in the patient are Recorlev community. take pleased and product. then know, number up the extremely you performance primary first properly a the XX% previously, increase of is strong collective drug and to a can with and we and couple referral on From

on will sales said, with being (ph) healthcare excellent. been a And revenue while take kick to only in. a providers too line. launch, to few That a meaningful into with be has based demand early the it's receptivity contribution weeks So

Xeris and while We since our -- patients We a are as pipeline call, are updates ago. syndrome. weeks a few already few of since Recorlev much with have team. And it's the through we're patients We're been professionals on with Cushing terms on drug, in healthcare for we last struggle the getting for and who weeks about excited reimbursement patients supporting prospects for very launch, getting only alternative another referrals. don't initiation, their our process Recorlev titration CareConnection

positive However, Phase we initiate X this study, did later still FDA we from which aim receive next induced year. on proposed a exercise our hypoglycemia response to

injection is Our still ongoing. subcutaneous levothyroxine weekly of potential [indiscernible] Phase X pharmacokinetic once evaluate as its study to a

dose the second begin in two third, next We quarter. levels have and higher later completed will dose the cohort dosing the

complete XXXX. We PK and expect doses proportionality from results study a report of out range this later and dose to in

quarter cash recent refinance. to to reiterate. over a ability commercial on exceptionally for detail financial especially the a cash for our quarter. generated our addition result our year, and of like first Before three the placement great position on the We to of Steve, our in strong our the I'd I products, hit as call confident We with our hand, had guidance with performance, cash revenue very feel from from debt private turn

it So turn over now, to I'll Steve.

Steve Pieper

was in issued net this of a my Thanks, product Paul. everyone. morning. press on remarks few results, which key the the revenue Good release Total are I focus financial will of the morning, million details by XX% both first revenue. strong for pro forma and patient demand increase $XX.X first underlying quarter, the was for XXXX product Keveyis. representing revenue quarter Net Gvoke a driven over

as in well XX% total which total of quarter, Gvoke quarter-over-quarter overall in Gvoke QX would XX% At While XX,XXX to prescriptions ending April quarter first the glucagon suggest an it quarter Gvoke recent in XX% to market growing than quarter, In the despite to weekly by reserve the results XXXX has strong launched the is was returns. overall declining prescriptions toping now share. in and data prescription we we glucagon first Recorlev actual NRx in made recognize immaterial Gvoke did revenue X%, had into achieved QX, our QX. the In of first approximately share the to trends the was the we most X% prescriptions from share approximately just more Recorlev NRx March, of continued Gvoke growth first continued quarter. QX. end returns capture its on XXth relative achieved first also historical the and with market. adjustment line based the momentum

product we a don't still product of We various and mode in factors. As on launch have product significant estimate is our history returns based returns. Gvoke

necessary. monitor a first quarter We returns of grew adjust patient perspective, will patients the by on to to drug as continue also XX% a XXXX. Keveyis our relative solid we quarter and from as had drug on reserve

the up furnish the full solid revenue. of we quarter based feel performance range ahead had underlying to to comments to net and $XXX we of on will of my business continue we $XXX year a on XXXX for revenue million product quarter growth the and driving Just wrap that it, looking fundamentals million within in the the first confident

and Gvoke, service expenses compared pharmaceutical was incurred ended down million Cost process related pharmaceutical development fourth months Research costs increased development Relative in period increase for same increased These $XX.X pipeline million by expenses across XX% $X.X key fourth quarter increases force costs primarily support of P&L. driven to period for approximately and XX, Keveyis This million. compared compared We million ‘XX programs programs. and March driven commercial lower to by $XX.X ’XX, decreased to to months increased and process million sold $X.X administrative ended increase Recorlev. sales general the commercial clinical quarter. $X.X research was sales the XXXX. were to and approximately XX, by our expenses XXXX, $X.X Moving quarter development This in March in the approximately three same and of the the the relative products. decrease to the driven an Selling, of goods XXXX. by to increased clinical of launch multiple higher first same three XXXX. primarily our was and of cost, million, period million by increased for by increase in or an also including development across the the $X.X to

the remaining increase change of the expenses to In costs. the of employee addition, $X restructuring given primarily approximately acquisition growth to the increase related was and company. related The in million general due was of Strongbridge, an

Xeris’ as Let I well these first important relative earnings mentioned quarter-over-quarter changes. fourth me on had to our absorb of the infrastructure with commercial to context increases some some that would year-end quarter not did context in prior the provide to as Strongbridge, other call on we sequential in XXXX acquisition Keveyis the which the March personnel, financial quarter ‘XX results. exist key of and

to of to only decreased is by addition commercial basis, in approximately of first ’XX infrastructure, relative important million fourth to actually this of the the on associated relative expanded fourth On costs quarter-over-quarter incurred SG&A first a in with our acquisition also quarter the Strongbridge XXXX. first the are decline in increase in quarter. SG&A costs of would seeing we though driving the quarter-over-quarter increases had with acquisition In is of Therefore, the the of some we relative included of related costs we Strongbridge. $XX had that with The terms context million first quarter, in an team acquisition We expenses Strongbridge of mentioned to approximately a of and and XXXX. first expenses. quarter the quarter the million mid-XXXX SG&A incurred associated endocrinology we to approximately in $X This a launch even the materially Recorlev associated Strongbridge decrease $XX expansion quarter also expenses expenses net quarter. basis,

we XXXX. cost As avoidance and approximately at on realize in reminder December that XX, $XX of March end consistent investments with cash reductions equally $XXX.X previous of cost the split had cash total and guidance, perspective, to Xeris believe of track XX, Strongbridge between XXXX. XXXX, and we to short-term From a million million cash, acquisition compared a synergies equivalents related million by as are $XXX.X

sheet with March. January and debt balance we pipe the in both $XX was Our finalized refinancing financing strengthened million by in Hayfin the

in in investing QX, year $XX XXXX. million, and higher accrued driven an related was was in to capital, increase accounts approximately Our sales coupled net working from burn for end to loss receivable a decline changes our cash by the which with from operating net quarter liabilities primarily

agreement new our Xeris with filing see You that a in Jefferies a ATM. quarterly sales entered today for will also into

We You but the will an of effectively future. in we of the a the additional recall was that place this do in financing, good equity and have new ATM to a but currently a ATM corporate for rise need should are doing need terminated. Strongbridge not previously, as housekeeping the acquisition matter had establishment with parent, financial

XXXX. up to by flexibility to Hayfin in with into and an March March the thereafter flow. debt the from entered and Bank. debt expect a current to until election $XX our working our fund facility capital. cash the March, base with us additional $XXX million additional at agreement significant we announced in would with we proceeds secured net Xeris to cash our available we draw $XX.X on $XX and date our business million to and closing We funds Finance $XXX loan flow facility of is repaid our by previous rapidly managed operating a we this constructed upon As end the remaining Valley of senior plan, year. Oxford capital of total provide business million by will we will with the operating $XX drew XXXX breakeven produce term increasing additional million of drive The the Silicon million Based end commercial capital year currently This plan, company is operating provides growing to million provide

reminder improve grow acquisition our from in over the XXXX last we see revenue to rate base we and a burn our continues of March, the of obligations in decline as cash As call with to the course a Strongbridge associated related costs. project

and end growth believe three our pipe recent To achieve flow from and a the we about with position, start strong the finish combined our current with further million on our from and We summarize, that breakeven Recorlev. debt the products we to year XXXX. with Hayfin. With very returns off cash are marketed the by $XXX revenue financing will million are $XX can early cash excited approximately received XXXX to the restructuring products commercial cash

We net are full XXXX affirming product million revenue to million. $XXX of $XXX our range year

to synergies to in a achieve have turn of I and perspective $XX end million R&D in position from And pipeline. quickly growth are fund we Paul. integrated Keveyis and We of by Recorlev solid in our XXXX. now a back Strongbridge Gvoke, we the Xeris and the call will will cash drive

Paul Edick

Steve. Thanks,

million say net heard, product just XXXX enough generated first in we good in off you quarter we and start approximately that $XX are can’t As revenue. for the a to we often

continued strong for growth We Gvoke. -- in growth share prescription

patients We to products. more of continue and add all to more our

our the the pipe position as advance refinance. We with pipeline debt strengthened continue cash levothyroxine. Steve our and of study to Phase X we with (ph) And mentioned, dramatically

recent if year $XX open line needing be our to well acquisition, addition our would net Strongbridge capital we're on And operations. of for a from the year-end position of for to million, please $XXX million in raise achieve end would our placement cash $XX We million commercial additional would are generated in from product products, purposes of capital refinance importantly, Given you hand and in ongoing to cash result Operator, by synergies our fund [indiscernible] cash $XXX breakeven exceptionally anticipate private M&A the of revenue return as only. strong order three cash And markets not we to $XXX assuming XXXX. on guidance cash to million to positioned guidance revenues flow XXXX and of the balance our questions.

Operator

Sandler. first Our Piper today Amsellem comes Instructions] [Operator you. question ahead. Thank from David Please go David, from

now Your line is open.

David Amsellem

Hey, thanks.

of just a So had couple questions.

a you're exposed adoption First, R&D any assets could and acquisition on in looks And patient to how who you to footprint about -- mentioned maybe is, could number provide like get talk metrics to at? provide should on [indiscernible] just also say? patient them? about the markets talk for they wanted the not back just to would agents? purposes, of patients position to you but of context of are number sense take have the one. the So M&A That's just target the wondering to go elaborate to patient I Recorlev risk if about early And you're specific what extent you capital of switches potential kind or two having you then unless to been I are Recorlev, Thanks. on access product you M&A Paul, I'm talk I if a looking or you from thinking in terms target, in other these getting just know are metrics, you're what about level a can extent days, the it's not which growing uptake, patient

Paul Edick

the Thanks Good those have morning, tried Recorlev we patients our which what track to our drug. in to to a to Thanks reimbursement plan. getting for we we through questions. to reiterate and on clear out the of Yeah. I'll well and paid set as track We're call. them contributing guidance lot on Recorlev metrics get degree a not for is believe -- And authorization in managing We their already guidance. We're David. the to We're referrals. What on insurance, remarks are and we're my We're with position give that working is, relative patient on the for prior patients convey for. process. we patients.

So that's the really can Recorlev, I best give early. it's you on

funds strongly plan In terms assuming to the cash I flow guidance. and have want breakeven, of the want to all the on reiterate, capital our of return to and we're through business strongly markets, very fund on we necessary our we the

critical ATM another but on in That your position. M&A a breakeven. for being -- good put we verge building to because or like want interesting company a and the housekeeping. So risk would if financial on we mass impact focused an that an point, us. Recorlev product to an has would cash a negative generating opportunity product and cash necessarily on revenue That incurs a place flow Strongbridge that's Keveyis not asset R&D there, said good we’re it's another did that and approved getting got out like it's add being to said, being be that's there's We're

David Amsellem

I at helpful. if on figures? not sense Thanks. sales net just here, all that, a apologize sales Can for I products And, That's just maybe you're and -- you're And give in specific this, why the Gvoke do specific of, just if a on us if to sales in a product Okay. missed you sneak not sales if possible. Keveyis just follow-up may position the providing disclosures. provide I and specifics

Paul Edick

Yeah.

Gvoke the it's but provide will gotten product product out We're launch for on still guidance is door. in basis. mode. saying, results, level early. a the Recorlev just what barely never too So not we'll committed year we've is is to total

If And you Gvoke first Recorlev you're you IQVIA, look quarter, math. didn't pretty following or more In less. do the the balance can at the and Keveyis is much. much contribute

David Amsellem

Okay. Thank you.

Operator

question David. you, comes ahead. next Thank from go Securities. today Roanna please from The SVB Roanna, Ruiz

now is open. line Your

Roanna Ruiz

morning, Good everyone. Great.

to question not anecdotally safety able efficacy in hearing follow how was first you understand your three growing a is and or front. physician launch? Are for So real Recorlev. Recorlev world about but awareness the product give for anything you're I of the specifics, about on I quarter curious

Paul Edick

efficacy, high few product already. season. quite had Their is (ph) working. the efficacy, a The been the XXA morning, got safety and from got great We up on receptivity activities only concerns all receptivity concerns and participating. is Roanna. had We're and far. it forward both We've expressed. Good no AACE about the conference to have looking we're excellent. has physicians having at awareness we to No And Endo so been we're we've and Endo AACE coming patients

So far, weeks, we're in a very feeling positive. few

Roanna Ruiz

think you questions I'm Great. quick bit. growth? the continued notice do be curious, And prescription seem BAQSIMI that for driving share is Gvoke. to We what a did stabilizing

So slight and might I'm differences the wondering BAQSIMI. Gvoke between of trends be some versus what causing

Paul Edick

we said and is head insulin we got at a and of as at They have we they it's this of to we of that get should more do which They insulin, start. with back of million would out through beginning during that urgency and healthcare ten just Well, Lilly’s in head start. patients they've with And faster on to or capture point, day we’re will To if when that that some share Lilly position months market. share goes would voice [indiscernible]. professionals their could also sense we you're our they to school likely the raising market well what But very very season, on we'll launched fair said a think we level a for the strong ten their rescue amongst all trend prescription I we've upward really product plus from people value and begin terms ready-to-use beginning the split extremely happens more insulin, If business the share. the to school from the rate said that get you glucagon. we've the I've fair since back in a had the to one, see got evenly. month market about point, X because

Roanna Ruiz

we I updates Yes. quick for products (ph) you approach exclusivity curious, if additional any forefront on was the life Understood. And pursuit patent end? one for have Keveyis. of the as

Paul Edick

don't have Yeah. update. We an

several process, to panel We're or appeals two. appeal continue We prosecute with the patents. in one

the to We continue very to try across work hard finish patent to line. get

Roanna Ruiz

a it. Thanks lot. Got

Operator

comes Vamil, question you. from Thank from ahead. Securities. The Mizuho Vamil please Divan go next today

now is line open. Your

Vamil Divan

Thanks a for Maybe of on question. couple following the my ones. earlier taking Great. up

with you. of Keveyis, of math you Gvoke, to little in to you case Lilly competition were the the BAQSIMI. you all? sort Can back anything side of terms if secure curious actually So just pricing Thank what's your on assumption generic sort And and should prescriptions these a one like patents math sales? the mentioned can of on sort potential sort is just that this there, doing net us than as there. the of get of trying mentioned in then, make, of maybe just to sense share our a more into we what on gross look or bit IP terms the give I'm It you net at more sales if discounting doing from kind before mean point of assumptions at they now base product

Paul Edick

Yeah.

through process, do the Keveyis is the haven't the takes on put we wouldn't expect help great the is, If PPP the any -- generic good didn't anything expect, company. we XXXX. to of there don't work patients. one, are shape a deal identified way the analysis identify in it And basically said of of part we front, till For We we're generic way really think I evidence that on the also we think physicians we've for the Keveyis patients the XXXX. seen think historically, and generic. we We

work. tough amount of So time generic to going a doing that same have is

a well. the that's company And product. recall, up by buying and go you the didn't was ended how terribly Strongbridge product launched If generic originally

historically, but our believe, open all So -- options And to including to authorized have diligent. up Generic. said being as we're very I've own end I we us

So I think a of portion a to business. there's significant way protect this

as far return, thing are in hit think the I the net Gvoke to to math Steve added your to net, As the to we the probably is Gvoke returns on mentioned, gross gross that reserve.

to want more. You talk

Steve Pieper

We Yeah. reserve. added to returns our

You'll primarily see in million And our into financials factors we when driven our but account actual returns. returns it in the by reserve, $X.X again, quarter. estimating take various

So I would say that was the impact. with We line don't comment in specifically on gross industry to retail net percentage, product. but for average

Paul Edick

on your there on pricing, in to impact And We're has good pretty been question negative no pricing. still shape.

Vamil Divan

of Okay. maybe than. on with there sequential SG&A. over you quarter, going your the What just bit guys guess, more We reported or trying a were of as I decline so And levels I and sort the higher least financial kind do Steve, quick a then a of quarter forward. that would one expect comments things little the for think decline. call you're you progression at you expenses your at try more forecasting to the here? quite these you we're the about follow of the bit second about side expect stabilize into think

Steve Pieper

think expect in what would would out an so I and Vamil. happened perspective, for probably the that question, I QX, see of balance it's what Good play really the stabilized, basically Yes, from you would year. SG&A

Vamil Divan

Thank Okay. much. very you Thanks.

Operator

from Robin go from ahead. Garner Robin, Thank please question today next Craig-Hallum. comes you. The

line is open. Your now

Robin Garner

perhaps on the Tetris plan [indiscernible] order and of Can -- timing further commercialized you even look and and the the into? morning. Good to expand

Paul Edick

but all UK. there question. the beginning I to the I there and catch didn't are that Tetris to in U.S. are formularies the I half, UK more second good morning, launched think and the Anyway, formularies Welcome the catch didn't in second They're of call, the on your in get payers Robin. the Robin half than

a very So to process, it a They're well. good start doing operationally difficult ordering They're long product. prescriptions, they're but getting patients. their and pretty they're getting is process off

I and in Scandinavian couple launch the -- still France, countries, Germany about beyond into that, business countries don't a them that. to is mid-year can suspects transfer through is to that at and countries of I We the think sequentially believe the got to they track likely to $XXX. XXXX and the all they're they and the they're for pricing in because Italy, make most on a a larger huge over to going Nordic, be whatever of course XXXX. other us Spain, equivalent sell rest other price contributor go it they of going

Robin Garner

Thank you on that. expanding for

Paul Edick

Yeah. Was question, there to another Robin? -- your

Robin Garner

awareness growth actually, One the question. change that patient around in units number share? as seeing just you're the I answers if that of revenue and for of question is per Gvoke additional your and continues terms your

Paul Edick

It's did see units more three. prescription creep seeing prescriptions. Yeah. be Interesting, right prescription two. units per we're launched, might stabilized the multiple prescription. about that the what of prescriptions right now up per to it's get we patients When things about per patients those two now, getting in average is average first units just But we about stabilized patient seeing get multiple where per not one is order to but more units, we're

Robin Garner

very you Thank much. Okay.

Operator

Thank you.

Oren from today from go Please H.C. question ahead. Livnat next Wainwright. comes Our

is Your open. now line

Oren Livnat

have through some the some reimbursement in more already stages them have I but On Do Thanks having and a of it's early understand revenue to all patients questions. did earliest the you've hope about taking couple. those got on really that, the you therapy already months I the when mention meantime. for at a you on last Can revenue my thinking I you this ago, couple material I Recorlev, looking and you've already we think talk forward, of point, call started extent patients? or added clearly, patients. producing

tight still eventually get a revenue they're, to? Now up. I follow if even lower per in they'll patient trading Thanks. up And than have at

Paul Edick

is The Yeah. answer yes.

until all actually authorization these As various payers. going insurance. we get know, are the But of prior require we're clearing a guidelines with you patients to

We are getting have that we're adding patients reimbursement week. and patients every

Oren Livnat

we're Okay. product, around therapy? future, about or small talking patient hopefully? you funnel orphan breakouts into more Will besides -- big difference. point think volumes, and revenue do active the talk indications, provide in we'll on At this obviously, Any we make you ever numbers about numbers metrics do the small added and a some for either

Paul Edick

talking Yeah. we'll volumes do regularly. be think pretty I they vary about because actually patient such small don't they numbers are and

our more metrics metrics quarter As that we're and can data the we of can on what in are provide all with forward that we that of We predict getting. reliable history are every that products. reassess we terms going get

results. said at never whether stabilize, as things and so never. or And as that we'll to look continue not we never product We've things provide level said grow we'll

Oren Livnat

I've And I product this onboarding the getting Can is, and prescribed the referred revenue? I theoretically process asked the Do patients presumably or before or with on producing you I therapy who's CareConnection process remind end remember the are on can't anyone adjudicated Recorlev? is get already before therapy but for your, us think just PA you process who through answer. apologize.

Paul Edick

when therapy and patient as of involved Yes, actually lot therapy. of to the is managed. ready partner The best Recorlev involved the all the doctors or get go, pharmacy they such request Insurance on in that that way ready patients patient to patients physicians specialty for CareConnections Patients is for the is be to physician, consultation involved the cleared. a have CareConnection initiate where Keveyis to matter partner go,

is talking physician's their to be the office how CareConnections. from to patients going managed, and happen, what maybe the to specialty going pharmacy, So side be know effects do from to them titration to go, the who's going expect, going what's how it's

in possible. actually a time initiated the the drug, as patient as position by on So to are they successful be is

Oren Livnat

this to approved getting patients I just have house it's transaction didn't does to if is smooth, to understand drug they guess frictionless and patient's but Apologies I the can get doc’s for necessarily is clear a possible or the it. fully sent make PA answer before just, before be

Paul Edick

to PA has be cleared, the has cleared. then be is initiated. Insurance drug to

Oren Livnat

Beautiful. sorry asking a for Keveyis, lot questions. And of on

all top And exact that? just growth. an is on some XX% price price believe bit ballpark total of -- translates mentioned patients without Can some growth a also material I that on talk giving to there that little about number, added there? churn how is terms or therapy in you You there year-over-year maybe benefit rear patient is year-over-year revenue your of,

Steve Pieper

churn. there, in growth on I turnover, do generally would would to growth Discontinuation right. churn We some in say is that think We a basis. the translates year-over-year I if do that have right? There revenue have there. patient

that's a option. think I safest

Oren Livnat

you time. Thank for Okay. the

Paul Edick

Oren. Thanks,

Operator

you. are additional this no at questions waiting Thank time. There

to So to Paul pass I'd like Edick the closing conference over remarks. for

Paul Edick

your Thanks support, capable again our company. for a good create as have to necessary Everybody strategy critical pharmaceutical execute mass become joining day. on fully and the and continued to to call everybody a really profitable for we

Operator

quarter conference first and Thank results Biopharma That concludes the call for your webcast. XXXX financial participation. you Xeris

may now You lines. your disconnect

Xeris Biopharma (XERS) 11 May 222022 Q1 Earnings call transcript